A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.

Inclusion Criteria:

• Confirmed relapsed/refractory lymphoid malignancies
• Previously treated with at least 2 therapeutic regimens
• ECOG performance < 2.
• Life expectancy of at least 3 months
• Adequate renal function
• Adequate hematologic status
• Adequate liver function
• Transfusion independent

Exclusion Criteria:

• Received other therapy (biological or drug) to treat cancer within 4 weeks prior to starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer treatment toxicity
• The use of systemic corticosteroids within 1 week of starting treatment with HGS1029
• Evidence of active bacterial, viral or fungal infection within 2 weeks before starting treatment with HGS1029
• Known HIV infection
• Positive for hepatitis B surface antigen or positive hepatitis C antibody
• Grade 2 or greater neuropathy
• Pregnant female or nursing mother
• Males or females who do not agree to use effective contraception during the study and through at least 30 days after the last dose of HGS1029